SCM
PHAT icon

Sterling Capital Management’s Phathom Pharmaceuticals PHAT Stock Holding History

Sterling Capital Management’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.2K Sell
756
-442
-37% -$5.04K ﹤0.01% 2331
2026
Q1 		$13.3K Sell
1,198
-551
-32% -$6.96K ﹤0.01% 2227
2025
Q4 		$29K Sell
1,749
-410
-19% -$5.86K ﹤0.01% 2030
2025
Q3 		$25.4K Buy
2,159
+1,256
+139% +$13K ﹤0.01% 2025
2025
Q2 		$8.66K Buy
903
+341
+61% +$1.89K ﹤0.01% 2230
2025
Q1 		$3.52K Sell
562
-305
-35% -$1.85K ﹤0.01% 2328
2024
Q4 		$7.04K Buy
867
+761
+718% +$9.42K ﹤0.01% 2311
2024
Q3 		$1.92K Buy
+106
New +$1.48K ﹤0.01% 2202

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Sterling Capital Management's PHAT Position: Q2 2026 in Review

Sterling Capital Management reduced its Phathom Pharmaceuticals (PHAT) stake by 37% in Q2 2026, selling an estimated $5.04K and leaving 756 shares worth $8.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2331.

Sterling Capital Management first reported a position in PHAT in Q3 2024 and has held it in 8 quarters since. The position peaked at $29K in Q4 2025. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Sterling Capital Management held 756 shares of Phathom Pharmaceuticals worth $8.2K as of Q2 2026.
  • Sterling Capital Management sold 442 Phathom Pharmaceuticals shares in Q2 2026, an estimated $5.04K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2331 holding.
  • Sterling Capital Management first reported a position in Phathom Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Phathom Pharmaceuticals position peaked at $29K in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.